20-F: Genmab Accelerates Growth with Merus Acquisition, Bolsters Late-Stage Pipeline

Genmab reports strong 2025 financial results driven by product sales and royalties, while strategically expanding its late-stage pipeline through the acquisition of Merus N.V. and advancing key proprietary assets.

Summary

• Genmab's revenue increased by 19% to $3,720 million in 2025, up from $3,121 million in 2024, primarily due to higher DARZALEX and Kesimpta royalties and increased EPKINLY net product sales.
• Operating profit for 2025 was $1,065 million, a 10% increase from $972 million in 2024.
• The company completed the acquisition of Merus N.V. for $8.017 billion on December 12, 2025, adding petosemtamab and Biclonics/Triclonics technology platforms to its portfolio.
• Petosemtamab received two Breakthrough Therapy Designations (BTDs) from the FDA for recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) and is in Phase III clinical development.
• Rinatabart Sesutecan (Rina-S) was granted Fast Track Designation (FTD) for platinum-resistant ovarian cancer (PROC) and BTD for recurrent or progressive endometrial cancer, with three Phase III trials initiated.
• EPKINLY (epcoritamab) received accelerated FDA approval in May 2023 for relapsed/refractory diffuse large B-cell lymphoma (DLBCL) and full FDA approval in November 2025 for relapsed/refractory follicular lymphoma (FL) in combination with R2.
• Tivdak (tisotumab vedotin) received full FDA approval in April 2024 for recurrent or metastatic cervical cancer and was approved in Europe and Japan in March 2025, marking Genmab's first independent launches in these regions.
• Research and development expenses increased by 14% to $1,606 million in 2025, driven by the ProfoundBio acquisition and pipeline expansion, including termination costs for the acasunlimab program.
• Genmab incurred $5.5 billion in non-convertible debt financing (Term Loan A, Term Loan B, Senior Secured Notes, Senior Unsecured Notes) to fund the Merus acquisition.
• The company's total assets grew to $12,873 million in 2025 from $6,414 million in 2024, largely due to the Merus acquisition.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong positive, reflecting significant strategic advancements through the Merus acquisition and robust performance of key products, despite increased debt and R&D expenses. The pipeline strength and commercial expansion are key drivers for future growth.

Positives

• Revenue increased by 19% in 2025 to $3,720 million, driven by strong product performance and royalties.
• Operating profit increased by 10% to $1,065 million in 2025.
• Strategic acquisition of Merus N.V. for $8.017 billion significantly expands the late-stage pipeline with petosemtamab.
• Petosemtamab received two Breakthrough Therapy Designations (BTDs) from the FDA, indicating potential for significant clinical improvement.
• Rina-S received Fast Track Designation (FTD) and Breakthrough Therapy Designation (BTD) and expanded into three Phase III clinical trials for ovarian and endometrial cancers.
• EPKINLY achieved full FDA approval for relapsed/refractory follicular lymphoma (FL) in combination with R2 and demonstrated improved PFS in a Phase III DLBCL trial.
• Tivdak secured regulatory approvals and launched independently in Europe (Germany) and Japan, establishing Genmab's commercial footprint outside the US and China.
• Novo Nordisk submitted a Biologics License Application (BLA) for Mim8, a DuoBody-based treatment for hemophilia A, potentially becoming the ninth approved medicine from Genmab's technology.
• Genmab's employee base grew to 3,029 at year-end 2025, reflecting organizational expansion and talent acquisition.

Negatives

• Research and development expenses increased by 14% to $1,606 million in 2025, partly due to termination costs for the acasunlimab program.
• The clinical development of acasunlimab was discontinued in December 2025 due to strategic focus and competitive landscape.
• Substantial indebtedness of $5.5 billion was incurred to finance the Merus acquisition, which could adversely affect financial condition and liquidity.
• Acquisition and integration related charges amounted to $185 million in 2025, primarily from professional fees and equity payouts related to the Merus acquisition.
• The company's equity ratio decreased significantly from 80% in 2024 to 45% in 2025 due to the Merus acquisition financing.

Risks

• Substantial majority of revenue comes from DARZALEX royalties, with patents expiring in the late 2020s (US in 2029, Japan in 2030, Europe in 2031), leading to potential material decline in revenue.
• New product launches or existing product expansions in new indications/territories face risks including supply constraints, commercial infrastructure delays, and pricing/reimbursement challenges.
• Rapid growth over recent years (employees from 548 in 2019 to 3,029 in 2025) puts significant demands on management and infrastructure, requiring effective management to avoid adverse effects.
• Acquisitions, such as Merus, may not realize anticipated benefits due to integration difficulties, failure to retain key employees, or unforeseen liabilities.
• Sales of products depend on market acceptance by physicians, patients, and healthcare payers, which may be limited by competition or unfavorable pricing/reimbursement.
• Reliance on collaboration partners for clinical development, manufacturing, and commercialization introduces risks if partners do not devote sufficient resources or if disputes arise.
• Biopharmaceutical product development is uncertain, time-consuming, and expensive, with a high risk of clinical trial failure or discontinuation.
• Reports of adverse events or safety concerns related to products or product candidates could negatively impact clinical trials, regulatory approvals, market acceptance, and reputation.
• Exposure to foreign exchange risk due to financial transactions in multiple currencies (USD, DKK, EUR, GBP) can adversely affect financial results.
• Cybersecurity risks, including ransomware and data breaches, could disrupt operations, lead to loss of intellectual property or personal data, and result in litigation or regulatory sanctions.
• Climate change and related regulations may negatively affect business operations, supply chain, and increase compliance costs.
• Inability to attract and retain talented and highly skilled employees in a competitive biotechnology industry.
• Legal proceedings, such as patent infringement lawsuits (e.g., Chugai) and trade secret complaints (e.g., AbbVie), are costly and time-consuming and could result in significant liabilities or loss of intellectual property rights.
• Government restrictions on pricing and reimbursement, including initiatives like the Inflation Reduction Act of 2022 (IRA) in the US, may negatively impact revenue generation.
• Products are subject to extensive post-approval regulation, which may result in significant additional expense, labeling restrictions, or market withdrawal.
• Potential for the company to lose its foreign private issuer status, leading to increased regulatory and compliance costs.
• Holders of American Depositary Shares (ADSs) may not be able to directly exercise voting rights or receive dividends as directly as shareholders.

Future Outlook

Genmab expects 2026 revenue to be between $4.1 billion and $4.4 billion, driven by higher royalties from DARZALEX and Kesimpta, and increased net product sales from EPKINLY and Tivdak. Operating expenses are projected to increase to $2.7 billion $2.9 billion due to investments in late-stage programs and launch readiness. Operating profit is anticipated to be between $0.9 billion and $1.4 billion. The outlook assumes no significant new agreements in 2026 and a USD/DKK exchange rate of 6.2. The company aims to integrate Merus, accelerate its late-stage pipeline (EPKINLY, Rina-S, petosemtamab) for potential launches and label expansions by 2027, and maintain financial discipline.

Management Comments

• "As we look back on 2025, I am proud of how Genmab advanced our strategy, strengthened our foundation, and stayed true to our purpose: improving the lives of patients through innovative, differentiated antibody medicines. We entered the year focused on disciplined execution and ended it poised for our next decade of sustainable growth." Jan van de Winkel, Ph.D., President & CEO
• "A pivotal step on that journey is our acquisition of Merus. This transaction enhances our late-stage portfolio with petosemtamab, a potential first-in-class bispecific for head and neck cancer with two BTDs from the FDA, reflecting its potential to meaningfully improve outcomes for patients." Jan van de Winkel, Ph.D., President & CEO
• "Importantly, Merus strengthens, not changes, our strategy as it accelerates our shift toward a fully integrated, 100%-owned medicines model. The addition of petosemtamab to our pipeline diversifies our sources of future revenue, reduces our dependence on royalties over time, and enhances our flexibility to invest in the next winners emerging from our research and development (R&D) engine." Jan van de Winkel, Ph.D., President & CEO
• "With EPKINLY, Rina-S and petosemtamab, we believe Genmab is positioned to deliver multiple potential launches and label expansions over the next several years, deepen our leadership in antibody innovation, and create durable, long-term value." Jan van de Winkel, Ph.D., President & CEO
• "Our differentiated approach to building a fully integrated biotech company started in the 2010s and has continued into the 2020s. Anchored by high-quality revenue growth and disciplined capital allocation, we have high conviction that we have the building blocks in place to continue our strong track record through the 2030s." Anthony Pagano, Executive Vice President and Chief Financial Officer

Industry Context

StockSavvy.ai notes that Genmab's strategic acquisition of Merus and its focus on expanding proprietary late-stage assets like petosemtamab and Rina-S aligns with a broader industry trend of pharmaceutical and biotechnology companies seeking to diversify revenue streams and reduce reliance on expiring patents. The continued success of partnered products like DARZALEX, Kesimpta, and Tivdak, alongside the advancement of proprietary bispecific antibodies and ADCs, positions Genmab competitively in the oncology and autoimmune disease markets. The industry is increasingly leveraging AI for drug discovery, a trend Genmab is also adopting, indicating a forward-looking approach to innovation. Intense competition in the multiple myeloma and cervical cancer therapy markets, with numerous approved treatments and investigational agents, underscores the importance of Genmab's differentiated product pipeline.

Comparison to Industry Standards

• EPKINLY is the first and only bispecific antibody approved for multiple B-cell malignancies in the US, Europe, and Japan, setting a high standard in this therapeutic area.
• Tivdak is the first and only ADC approved for recurrent or metastatic cervical cancer in the US, Europe, and Japan, and the only ADC with demonstrated overall survival data in this setting compared to chemotherapy, indicating a leading position.
• Petosemtamab's two BTDs from the FDA for HNSCC suggest it has demonstrated substantial improvement over available therapies, a strong indicator of competitive potential against established EGFR-targeting antibodies like Lilly's Erbitux and emerging EGFR-targeted ADCs.
• The discontinuation of acasunlimab reflects a strategic prioritization in a competitive landscape, a common practice in the biopharmaceutical industry to focus resources on the most promising assets.
• Genmab's growth from 548 employees in 2019 to 3,029 in 2025 demonstrates significant scaling, comparable to other rapidly expanding biotech firms, but also highlights the challenges of managing such growth effectively.

Management Changes

Corporate Governance

Legal Proceedings

• Chugai Patent Infringement Complaint: Chugai filed lawsuits in Japan against AbbVie's and Genmab's Japanese subsidiaries in 2024 and September 2025, asserting infringement of four Japanese patents related to EPKINLY (epcoritamab) and claiming damages and injunctive relief. Genmab and AbbVie refute these allegations and intend to vigorously defend the claims.
• AbbVie Rina-S Trade Secret Complaint: AbbVie filed a complaint in the US District Court for the Western District of Washington (Seattle) in Q1 2025, alleging misappropriation of trade secrets related to Rina-S and other ADC pipeline products by ProfoundBio (acquired by Genmab) and former AbbVie employees. AbbVie is seeking damages and broad injunctive relief. In Q4 2025, AbbVie filed a similar complaint with the US International Trade Commission (ITC) seeking to exclude certain ADC products from importation. Genmab categorically refutes these allegations and will vigorously defend the company.

Related Party Transactions

• Employment agreements and equity compensation grants were made to members of Executive Management in the ordinary course of business.
• Remuneration packages were provided for members of the Board of Directors.
• Intercompany transactions and services occurred between Genmab A/S and its subsidiaries in areas such as product sales, R&D, SG&A, finance, and management, which are eliminated in consolidated financial statements.
• Genmab A/S provided credit facilities to its subsidiaries for funding activities.
• During Q4 2024, ProfoundBio US (an indirect subsidiary) sold its intangible assets to Genmab A/S, resulting in $1.9 billion dividend income for Genmab A/S and a $1.5 billion impairment loss on investment in subsidiaries.

Stakeholder Impact

• **Shareholders**: Potential for increased long-term value through pipeline expansion and commercialization success, but also exposure to increased debt and R&D costs. Legal proceedings could impact share value.
• **Employees**: Rapid growth and acquisitions (Merus, ProfoundBio) lead to increased headcount and expanded career development opportunities. Discontinuation of programs like acasunlimab impacts specific teams. Compensation includes share-based incentives.
• **Customers/Patients**: Development and commercialization of innovative antibody medicines (EPKINLY, Tivdak, Rina-S, petosemtamab) aim to address unmet medical needs and improve treatment outcomes for cancer and other serious diseases. Patient access and affordability are key considerations.
• **Collaboration Partners**: Continued reliance on partners like J&J, AbbVie, Pfizer, Novartis, and Amgen for development, manufacturing, and commercialization, with shared risks and rewards. New collaborations, such as with Halozyme for petosemtamab SC formulation, expand partnerships.
• **Creditors**: Substantial indebtedness incurred for the Merus acquisition increases financial leverage, subject to financial covenants and potential prepayment obligations.
• **Regulatory Authorities**: Ongoing compliance with extensive regulations (FDA, EMA, MHLW) for product approval, manufacturing, marketing, and post-approval surveillance. Legal challenges related to patents and trade secrets involve regulatory scrutiny.

Next Steps

• Integrate Merus to preserve momentum on the petosemtamab program and prepare for potential launch in 2027.
• Accelerate the development of the late-stage pipeline, delivering key clinical readouts across epcoritamab and Rina-S, while preparing for potential label expansions and launches.
• Continue to deliver on capital allocation priorities, maintaining financial discipline while focusing investments on high-growth opportunities.
• Monitor the effectiveness of hedging instruments for interest rate risk on partially swapped Term Loans, effective January 2026.
• Register the Trustee and Notes Collateral Agent with the Danish Financial Supervisory Authority in accordance with the Danish Capital Markets Act.

Key Dates

Recommendation

Genmab's strategic acquisition of Merus, coupled with the strong performance and continued advancement of its proprietary and partnered pipeline, positions the company for significant long-term growth. The multiple Breakthrough Therapy Designations for petosemtamab and Rina-S, along with the successful global launches and label expansions of EPKINLY and Tivdak, demonstrate robust innovation and commercial execution. While increased debt and R&D expenses are noted, these are strategic investments aimed at diversifying revenue streams and reducing reliance on expiring patents, which is a prudent long-term move. The company's strong financial foundation and clear strategic vision support a positive outlook for investors seeking exposure to a leading biotechnology firm with a promising oncology pipeline.

Keywords

Biotechnology, Oncology, Antibody Therapeutics, Merus Acquisition, Petosemtamab, Rinatabart Sesutecan, EPKINLY, Tivdak, DARZALEX, Clinical Development, SEC Filing, Financial Results, Pharmaceuticals, Drug Development, Corporate Governance, Risk Management, Capital Raise, Senior Notes, Biologics, ADC, Bispecific Antibody